Filing Flows › Bausch Health Companies (BHC) › Q3 2026 › vs Q3 2025
Bausch Health Companies (BHC) Q3 2026 vs Q3 2025 (year over year)
Bausch Health Companies's revenue rose $260M (+10%) from $2.7B in Q3 2025 to $2.9B in Q3 2026. The biggest changes: Product sales +$255M (+10%); Other revenues +$5.0M (+21%). Operating margin 33.4% against 23.1% (+10.3 pts).
Bausch Health Companies, Q3 2026: revenue $2.9B (+10% year over year), operating margin 33.4%, net earnings $436M, operating cash flow $814M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 33.4% | 23.1% | +10.3 pts |
| Net margin | 14.8% | 6.7% | +8.1 pts |
| Free cash flow margin | 25.4% | 11.7% | +13.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product sales | $2.9B | $2.7B | $255M | +10% |
| Other revenues | $29.0M | $24.0M | $5.0M | +21% |
| Revenue | $2.9B | $2.7B | $260M | +10% |
| Operating profit | $983M | $619M | $364M | +59% |
| Costs & expenses | $2.0B | $2.1B | −$104M | -5% |
| Pre-tax earnings | $597M | $218M | $379M | +174% |
| Other expense, net | $386M | $401M | −$15.0M | -4% |
| Research & development | $141M | $166M | −$25.0M | -15% |
| SG&A | $834M | $795M | $39.0M | +5% |
| Other operating costs | $983M | $1.1B | −$118M | -11% |
| Net earnings | $436M | $179M | $257M | +144% |
| Minority interests | $10.0M | $2.0M | $8.0M | +400% |
| Income tax | $151M | $37.0M | $114M | +308% |
| Depreciation & amortization | $284M | $306M | −$22.0M | -7% |
| Share-based compensation | $52.0M | $43.0M | $9.0M | +21% |
| Working capital & other | $42.0M | −$123M | $165M | — |
| Operating cash flow | $814M | $405M | $409M | +101% |
| Free cash flow (OCF − capex) | $748M | $314M | $434M | +138% |
| Capital expenditures | $66.0M | $91.0M | −$25.0M | -27% |
Questions
How much did Bausch Health Companies's revenue grow year over year in Q3 2026?
Bausch Health Companies's revenue rose $260M (+10%) from $2.7B in Q3 2025 to $2.9B in Q3 2026.
What drove Bausch Health Companies's revenue change in Q3 2026?
Product sales +$255M (+10%); Other revenues +$5.0M (+21%).